L-Arginine and Sickle Cell Disease

NCT01142219 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Sickle Cell Disease

Interventions

DRUG: L-arginine
DRUG: Placebo

Sponsor

Hospital de Clinicas de Porto Alegre

Collaborators

[object Object]
[object Object]
[object Object]